MK-7965

Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related… Expand

KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit… Expand

INTRODUCTION Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with… Expand

OBJECTIVES Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been… Expand

INTRODUCTION Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene… Expand

Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been… Expand

After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase… Expand